607
Participants
Start Date
September 12, 2022
Primary Completion Date
July 15, 2027
Study Completion Date
April 10, 2029
Acalabrutinib
Dose formulation: Capsule or Tablet
Venetoclax
Dose formulation: Tablet
Obinutuzumab
Dose formulation: Injection
Research Site, Budapest
Research Site, Waratah
Research Site, Clayton
Research Site, Geelong
Research Site, Debrecen
Research Site, Nedlands
Research Site, New York
Research Site, New Hyde Park
Research Site, Buffalo
Research Site, Rochester
Research Site, Philadelphia
Research Site, Charlottesville
Research Site, Charlotte
Research Site, Jacksonville
Research Site, Montpellier
Research Site, Tours
Research Site, Nashville
Research Site, Cleveland
Research Site, St Louis
Research Site, Longmont
Research Site, Salt Lake City
Research Site, Tucson
Research Site, Eugene
Research Site, Seattle
Research Site, Seattle
Research Site, La Jolla
Research Site, Boston
Research Site, Hradec Králové
Research Site, Ostrava - Poruba
Research Site, Pilsen
Research Site, Bydgoszcz
Research Site, Gdansk
Research Site, Katowice
Research Site, Krakow
Research Site, Lódz
Research Site, Lublin
Research Site, Barcelona
Research Site, Palma de Mallorca
Lead Sponsor
AstraZeneca
INDUSTRY